Mechanism of action REX 001
01/03/2020
Mechanism of action REX 001
Related news
12/07/2022
London, UK, 12 July 2022: Ixaka Ltd, an integrated cell and gene therapy company focused on boosting the natural power…
Read More
27/06/2022
REX-001 is an autologous multi-cell therapy (MCT) in development for the treatment of chronic limb-threatening ischemia (CLTI) in patients with…
Read More
21/03/2022
London, UK, 21 March 2022– Ixaka Ltd, an integrated cell and gene therapy company, today announces an expansion of its…
Read More